Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 174

Similar articles for PubMed (Select 12904846)

1.

Late cytomegalovirus disease following liver transplantation.

Shibolet O, Ilan Y, Kalish Y, Safadi R, Ashur Y, Eid A, Shouval D, Wolf D.

Transpl Int. 2003 Dec;16(12):861-5. Epub 2003 Aug 5.

PMID:
12904846
2.

Delayed-onset primary cytomegalovirus disease after liver transplantation.

Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.

Liver Transpl. 2007 Dec;13(12):1703-9.

3.

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.

Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV.

J Infect Dis. 2001 Dec 1;184(11):1461-4. Epub 2001 Oct 23.

4.

Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.

Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, Gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou G, Carratalà J, Torre-Cisneros J, Pahissa A; RESITRA.

Clin Infect Dis. 2008 Jan 1;46(1):20-7. doi: 10.1086/523590.

5.

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA.

Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.

6.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3182-6.

PMID:
16213344
7.

Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.

Transplant Proc. 2007 Sep;39(7):2228-30.

PMID:
17889146
8.

Deferred versus prophylactic therapy with gancyclovir for cytomegalovirus in allograft liver transplantation.

Lianghui G, Shusen Z, Tingbo L, Yan S, Weilling W, Anwei L.

Transplant Proc. 2004 Jun;36(5):1502-5.

PMID:
15251371
9.

Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.

Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, Pedersen RA, Dierkhising RA, Patel R, Razonable RR.

J Heart Lung Transplant. 2007 Oct;26(10):1019-24.

PMID:
17919622
10.
11.

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.

Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P, Klingebiel T, Dietz K, Löffler J, Bokemeyer C, Müller CA, Kanz L.

Bone Marrow Transplant. 2000 Apr;25(7):757-63.

12.

Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.

Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV.

Liver Transpl. 2008 Feb;14(2):240-4. doi: 10.1002/lt.21362.

13.

Late hepatic artery thrombosis after orthotopic liver transplantation.

Gunsar F, Rolando N, Pastacaldi S, Patch D, Raimondo ML, Davidson B, Rolles K, Burroughs AK.

Liver Transpl. 2003 Jun;9(6):605-11.

14.

A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.

Madan RP, Campbell AL, Shust GF, Kahn AR, Wistinghausen B, Posada R, Kerkar N, Shneider BL, Emre S, Herold BC.

Transplantation. 2009 May 15;87(9):1318-24. doi: 10.1097/TP.0b013e3181a19cda.

PMID:
19424031
15.

Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.

Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Asberg A, Degré M, Fauchald P, Rollag H.

Nephrol Dial Transplant. 2003 Sep;18(9):1899-908.

16.

Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.

Brady RL, Green K, Frei C, Maxwell P.

Transpl Infect Dis. 2009 Apr;11(2):106-11. doi: 10.1111/j.1399-3062.2008.00356.x.

PMID:
19054381
17.
18.

Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients.

Dupuis R, Harris M, Gillis K, Gerber D, Fair J, Watson R, Koslowski T, Andreoni K.

Transplant Proc. 2007 Dec;39(10):3266-70.

PMID:
18089368
19.

Risk factors associated with cytomegalovirus-positive antigenemia in orthotopic liver transplant patients.

Hoppe L, Bressane R, Lago LS, Schiavo FL, Marroni CA, Keiserman DR, Brandão AB, Júnior AM, Cassal AP, Zanotelli ML, Cantisani GP.

Transplant Proc. 2004 May;36(4):961-3.

PMID:
15194334
20.

Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports.

Boobes Y, Al Hakim M, Dastoor H, Bernieh B, Abdulkhalik S.

Transplant Proc. 2004 Jul-Aug;36(6):1841-3.

PMID:
15350493
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk